Progress of study on sideroblastic anemia and its possible gene therapy--review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 524-528, 2005.
Artículo
en Chino
| WPRIM
| ID: wpr-356521
ABSTRACT
It was thought that delta-aminolevulinate synthase (ALAS) is the rate-limiting enzyme in the heme biosynthetic pathway. Actually there are two isozymes of ALAS and ALAS2 (erythroid delta-aminolevulinate synthase), they play the leading role in the hemoglobin biosynthetic pathway. Mutations in ALAS2 gene causes X-linked sideroblastic anemia (XLSA). About 25 different mutations in ALAS2 gene have been identified in XLSA patients and two of them were reported by our laboratory. It is possible to cure the patients with XLSA by gene therapy because it is a single gene disorder.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Terapéutica
/
Terapia Genética
/
Cromosomas Humanos X
/
Genética
/
5-Aminolevulinato Sintetasa
/
Anemia Sideroblástica
/
Ligamiento Genético
/
Métodos
/
Mutación
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2005
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS